Aequus BioPharma was formed in May, 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. (CTI) to discover, develop and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Aequus is currently funded through a convertible note held by CTI. An Aequus Corporate Fact Sheet (PDF) is available for download.
MARKET
With current worldwide sales of $51 billion, ramping to $87 billion by 2010, therapeutic proteins represent 64% of all biopharmaceutical sales and 8.5% of the $602 billion world pharmaceutical market. The Aequus Genetic Polymer technology platform can be applied to a wide variety of biotherapeutic candidates in this rapidly expanding market.
CORPORATE FACT SHEET
This brief summary of Aequus BioPharma's origin, technology, market and development plans describes the company's potential impact on the development, manufacture and commercialization of novel and follow-on biopharmaceuticals
